Global Genetic Testing Services Market Size By Type (Prenatal Testing, Newborn Screening), By Application (Hospital-based Laboratories, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023...

The Global Genetic Testing Services Market was valued at USD 18.7 billion in 2023 and is projected to reach USD 47.5 billion by 2031, growing at a CAGR of 12.4% during the forecast period of 2023–2031. The market's rapid growth is fueled by increasing awareness of personalized medicine, rising incidences of genetic disorders and chronic conditions, and advancements in genomic technologies. Genetic testing plays a pivotal role in diagnosing hereditary diseases, cancer, pharmacogenomics, and prenatal conditions, significantly improving patient care and treatment outcomes.

Drivers:

1. Surge in Personalized Medicine Initiatives:

The rise in precision healthcare has prompted the adoption of genetic testing to tailor therapies based on individual genetic makeup, especially in oncology, cardiology, and neurology.

2. Technological Advancements in Genomics:

Innovations such as next-generation sequencing (NGS), CRISPR-based diagnostics, and AI-driven bioinformatics are making genetic testing faster, more accurate, and cost-effective.

3. Increasing Prevalence of Genetic Disorders and Cancer:

The growing burden of inherited diseases and cancer is propelling demand for early diagnostic solutions, with genetic tests offering significant predictive and diagnostic value.

Restraints:

1. High Cost and Limited Reimbursement:

Despite falling sequencing costs, comprehensive genetic tests remain expensive. Reimbursement issues in several regions limit accessibility for patients.

2. Ethical, Legal, and Social Issues (ELSI):

Concerns around genetic privacy, data misuse, and discrimination hinder market growth, particularly in countries with less stringent data protection frameworks.

Opportunity:

1. Expansion into Emerging Economies:

Countries like India, Brazil, and China present high-growth opportunities due to expanding healthcare infrastructure, rising awareness, and supportive regulatory reforms.

2. Growing Direct-to-Consumer (DTC) Testing Market:

Increased consumer interest in ancestry, wellness, and disease risk prediction is fueling demand for DTC genetic testing services offered through online platforms.

Market by System Type Insights:

By system type, the Predictive & Presymptomatic Testing segment held the largest market share in 2023. These tests are widely used to assess the likelihood of developing genetic conditions such as BRCA-related cancers and Huntington’s disease. Their preventive potential and increasing public awareness are driving segment dominance. Meanwhile, the Pharmacogenomic Testing segment is poised for fastest growth, propelled by demand for personalized drug therapy solutions.

Market by End-use Insights:

In terms of end-use, Hospitals & Clinics emerged as the leading segment, contributing over 50% of revenue in 2023. This is attributed to increased integration of genetic testing in clinical workflows for diagnosis and treatment. However, the Direct-to-Consumer (DTC) segment is expected to witness robust growth during the forecast period due to increased demand for at-home testing and health monitoring.

Market by Regional Insights:

North America dominated the genetic testing services market in 2023, driven by the region’s strong research ecosystem, presence of key players, and favorable regulatory environment. However, Asia-Pacific is projected to record the highest CAGR, owing to rising healthcare investments, growing awareness of genomic health, and increasing adoption of advanced diagnostics.

Competitive Scenario:

Key players in the global genetic testing services market include 23andMe Inc., Illumina Inc., Myriad Genetics, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Invitae Corporation, Eurofins Scientific, Centogene AG, and Color Genomics. These companies are focused on partnerships, acquisitions, and the development of AI-driven platforms to enhance diagnostic accuracy and expand service offerings.

Key Market Developments:

2023: Illumina Inc. launched a new AI-integrated whole genome sequencing platform to improve clinical diagnostics.

2024: Myriad Genetics partnered with a major oncology network to expand its hereditary cancer testing services across Europe.

2025: 23andMe announced a strategic DTC collaboration with a leading telehealth provider to offer integrated genetic counseling services online.

Scope of Work – Global Genetic Testing Services Market

Report Metric Details

Market Size (2023) USD 18.7 Billion

Projected Market Size (2031) USD 47.5 Billion

CAGR (2023–2031) 12.4%

Key Segments by System Type Predictive & Presymptomatic Testing, Carrier Testing, Pharmacogenomic Testing, Prenatal & Newborn Testing

Key Segments by End-Use Hospitals & Clinics, Diagnostic Laboratories, Direct-to-Consumer (DTC)

Leading Region North America

Key Players 23andMe, Illumina, Myriad Genetics, Roche, Thermo Fisher, Quest Diagnostics

Growth Drivers Precision medicine, Genetic disorder prevalence, Technology advancements

Opportunities Emerging markets, Expansion of DTC models

FAQs:

1) What is the current market size of the Global Genetic Testing Services Market?

The market was valued at USD 18.7 billion in 2023.

2) What is the major growth driver of the Global Genetic Testing Services Market?

The major growth driver is the increasing adoption of personalized medicine and advancements in genomic technologies.

3) Which is the largest region during the forecast period in the Global Genetic Testing Services Market?

North America is the largest region, driven by early adoption of genetic testing and favorable healthcare policies.

4) Which segment accounted for the largest market share in the Global Genetic Testing Services Market?

The Predictive & Presymptomatic Testing segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Genetic Testing Services Market?

Key players include 23andMe, Illumina, Myriad Genetics, Thermo Fisher Scientific, and Roche.